Retrospective study evaluating the performance of risk factors for invasive mold infections in liver transplantation

Karyna M Neyra1, Kyle D Brizendine1

  • 1Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio.

Abstract

Insights

Invasive mold infections after liver transplant are serious. Traditional risk factors did not accurately predict mold infection risk in this study, suggesting a need for center-specific strategies.

Area of Science:

  • Transplant Infectious Diseases
  • Mycology
  • Immunocompromised Host Infections

Background:

  • Invasive mold infections post-liver transplant carry high mortality.
  • Current guidelines recommend antifungal prophylaxis based on specific risk factors.
  • The efficacy of these risk factors in identifying infection risk across different transplant centers is unclear.

Purpose of the Study:

  • To evaluate the association between traditional risk factors and invasive mold infection in liver transplant recipients.
  • To assess the impact of antifungal prophylaxis on mold infection rates.
  • To determine the predictive value of established risk factors at a single transplant center.

Main Methods:

  • Retrospective analysis of adult liver transplant recipients from 2010-2014.
  • Identification of patients with and without traditional risk factors for mold infection.
  • Comparison of mold infection incidence and antifungal prophylaxis use between groups.

Main Results:

  • The overall incidence of invasive mold infection was 0.9% (5/534).
  • Patients with risk factors had a similar incidence (0.78%) compared to those without (0.98%).
  • Antifungal prophylaxis in 18% of high-risk patients prevented infections; 82% without prophylaxis had a 0.95% infection rate.

Conclusions:

  • Traditional risk factors for mold infection in liver transplant recipients demonstrated poor predictive performance.
  • Transplant center-specific data are crucial for developing effective antifungal prophylactic strategies.
  • Further research is needed to identify alternative risk factors for targeted antifungal use.